Cargando…

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma

Detalles Bibliográficos
Autor principal:	Dogan, Ahmet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153519/ https://www.ncbi.nlm.nih.gov/pubmed/36263845 http://dx.doi.org/10.3324/haematol.2022.281700

Ejemplares similares

Immunotherapies in Non-Hodgkin’s Lymphoma
por: Bezombes, Christine, et al.
Publicado: (2021)

Second cancer risk following Hodgkin lymphoma
por: Sud, Amit, et al.
Publicado: (2017)

Genetics of classical Hodgkin Lymphoma
por: Schiavoni, Gianluca, et al.
Publicado: (2018)

Mucocutaneous Paraneoplastic Syndrome Secondary to Classical Hodgkin’s Lymphoma
por: Jurkovic, Jenna, et al.
Publicado: (2019)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

Peripheral T Cell Non-Hodgkin's Lymphoma following Treatment of Hodgkin's Lymphoma
por: Chang, Sun Hee, et al.
Publicado: (2015)

Non-Hodgkin Lymphoma Secondary to Hodgkin Lymphoma in an Adult Patient With Nijmegen Breakage Syndrome
por: Braitsch, Krischan, et al.
Publicado: (2018)

Assessment of the Neutrophil-Lymphocyte Ratio in Classic Hodgkin Lymphoma Patients
por: Dogan, Ali, et al.
Publicado: (2019)

The Grey Zones of Classic Hodgkin Lymphoma
por: Bosch-Schips, Jan, et al.
Publicado: (2022)

The molecular mechanisms of classic Hodgkin's lymphoma.
por: Felberbaum, Rachael S.
Publicado: (2005)

Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)

Controversies in the Treatment of Classical Hodgkin Lymphoma
por: Eichenauer, Dennis A., et al.
Publicado: (2018)

Risk of non-Hodgkin's lymphoma following tuberculosis
por: Askling, J, et al.
Publicado: (2001)

Plasma cells in classical Hodgkin lymphoma: a new player in the microenvironment?
por: Visser, Lydia
Publicado: (2018)

Treatment outcomes in classic Hodgkin lymphoma: 5‐year update from the Brazilian Hodgkin Lymphoma Registry
por: Biasoli, Irene, et al.
Publicado: (2023)

Non-Hodgkin's Lymphomas
por: Proctor, S.J.
Publicado: (1994)

Bone marrow involvement by classic Hodgkin lymphoma
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Aberrant synaptophysin expression in classic Hodgkin lymphoma
por: Im, Soyoung, et al.
Publicado: (2022)

Bob-1 is expressed in classic Hodgkin lymphoma
por: Abd El All, Howayda S
Publicado: (2007)

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma
por: Relecom, Allan, et al.
Publicado: (2020)

MicroRNA signature in classical Hodgkin lymphoma
por: Paczkowska, Julia, et al.
Publicado: (2021)

Current directions in the treatment of classical Hodgkin lymphoma
por: Keller, Frank G., et al.
Publicado: (2023)

CAR-T Cell Therapy for Classical Hodgkin Lymphoma
por: Katsin, Mikalai, et al.
Publicado: (2023)

Divergent clonal evolution of a common precursor to mantle cell lymphoma and classic Hodgkin lymphoma
por: Tashkandi, Hammad, et al.
Publicado: (2019)

Clinical Management of Long-Term Survivors after Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma
por: Bari, Alessia, et al.
Publicado: (2022)

Diet and non-Hodgkin's lymphoma risk
por: Mozaheb, Zahra, et al.
Publicado: (2012)

Case report: Composite mantle cell lymphoma and classical Hodgkin lymphoma
por: Wang, Hongyu, et al.
Publicado: (2023)

Secondary Sclerosing Cholangitis and Hodgkin’s Lymphoma
por: Abedi, Seyed Hassan, et al.
Publicado: (2015)

CD4 T cells: the complicated key to unlocking the immune environment of classical Hodgkin lymphoma
por: Gandhi, Maher K., et al.
Publicado: (2022)

Association of HHV-6 with Hodgkin and non Hodgkin lymphoma
por: Kiani, Hadis, et al.
Publicado: (2016)

Composite lymphoma associating diffuse large B‐cell lymphoma with classical Hodgkin lymphoma
por: Lauwers, Maïlis, et al.
Publicado: (2022)

Checkpoint CD47 expression in classical Hodgkin lymphoma
por: Gholiha, Alex Reza, et al.
Publicado: (2022)

Novel Approaches in Molecular Characterization of Classical Hodgkin Lymphoma
por: van Bladel, Diede A. G., et al.
Publicado: (2022)

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future
por: Richardson, S. E., et al.
Publicado: (2011)

Hemophagocytic Lymphohistiocytosis in a Patient with Classical Hodgkin Lymphoma
por: Hyun, G., et al.
Publicado: (2016)

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
por: Meti, Nicholas, et al.
Publicado: (2018)

Combined linkage and association analysis of classical Hodgkin lymphoma
por: Lawrie, Alastair, et al.
Publicado: (2018)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
por: Voorhees, Timothy J, et al.
Publicado: (2020)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)

Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
por: De Re, Valli, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4cqtarptu3outupe7grivu7kvh